13 Jun '17, 4pm

Spotlight Clinical Trial for AML patients! Check it out here:

This is a randomized, multicenter, open-label, Phase 2 study of the oral SINE™ compound selinexor in patients 60 years of age or older with relapsed or refractory AML who are ineligible for standard intensive chemotherapy and/or transplantation. In the Selinexor in Older Patient with Relapsed/Refractory AML (SOPRA) study, Karyopharm is evaluating approximately 170 patients who have AML that has relapsed after, or was refractory to, first line therapy. Patients are randomized in a 2:1 fashion to selinexor provided orally twice weekly in a dose of 60mg plus best supportive care (BSC) versus one of three physician choices. Patients must have received at least one prior line of AML therapy given at standard doses and must have progressed after their most recent therapy. Prior therapy must have included at least two cycles of a hypomethylating agent. Physician choices include (...

Full article: http://www.aamds.org/treatments/clinical-trials/selinexor...

Tweets

You can help patients and researchers and honor...

aamds.org 13 Jun '17, 6pm

You can designate your gift as a memorial or tribute when you make your gift online, by mail or by telephone. The honoree ...

MDS Trial is now enrolling patients:

aamds.org 20 Jun '17, 12pm

Patients with higher-risk MDS failing HMA treatment (targeted patient population) have no approved medical therapy and a s...

Gross! Unsterilized Dental Tools Used on Dozens of Patients in Singapore

Gross! Unsterilized Dental Tools Used on Dozens...

sputniknews.com 12 Jun '17, 10pm

An estimated 72 patients at the National Dental Centre Singapore (NDCS) were treated with tools and implements that had no...